Csl Limited

Other

The University of Melbourne

The University of Queensland

The University of New South Wales

Csl Limited, A.c.n.

Elizabeth Ann Webb

Stirling John Edwards

Ian Hector Frazer

John Cooper Cox

Linda J Rothel

Ian George Barr

Bruce Carter Ross

Dianna M Hocking

Michelle A Patterson

Catherine T Agius

Mai B Margetts

Christopher Vincent Doidge

Nigel Alan John McMillan

Mary Brigid Margetts

Mark Philip Williams

Margaret Bridget Holland Moloney

Adrian Lee

Stuart L Hazell

Fiona Jane Radcliff

Dianna Margaret Hocking

Phillip Sutton

Mai Brigid Margetts

Linda Joy Rothel

Catherine Therese Agius

Michelle Anne Patterson

The present invention relates to isolatedpolypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 110; SEQ. ID. NO. 111; SEQ. ID. NO. 112; SEQ. ID. NO. 113; SEQ ID NO: 120; SEQ. ID. NO. 123; SEQ. ID. NO. 124; SEQ. ID. NO. 125; SEQ. ID. NO. 130; SEQ. ID. NO. 131; SEQ. ID. NO. 132; SEQ. ID. NO. 133; SEQ. ID. NO. 135; SEQ. ID. NO. 136; SEQ. ID. NO. 137; SEQ. ID. NO. 138; SEQ. ID. NO. 143; SEQ. ID. NO. 144; SEQ. ID. NO. 145; SEQ. ID. NO. 146; SEQ. ID. NO. 147; SEQ. ID. NO. 148; and amino acid sequences at least 95% identical thereto.

[object Object]

An isolated polypeptide and immunogenic fragments thereof are described together with their variants and derivatives as novel immunogenic agents for treating or preventinginfection in a mammalian host. The polypeptide comprises a C-terminal portion of acatalase, which portion lacks significant amino acid sequence identity with human catalase, wherein the polypeptide is other than full-lengthcatalase.

Polypeptide fragments comprising c terminal portion of helicobacter catalase

The present invention relates to isolatedpolypeptides and nucleotides. The polypeptides include;

Protective Helicobacter antigens, especially H. pylori antigens, and the use of these antigens for the treatment of or prevention of, gastroduodenal disease associated with H. pylori infection.

Protective helicobacter antigens

A papillomavirus polyprotein construct comprises at least two amino acid sequences fused directly or indirectly together, each of the sequences being the sequence of an early ORF protein of papillomavirus or an immunogenic variant or fragment thereof, and at least one of said sequences being other than the E6 or E7 protein sequence or an immunogenic variant or fragment thereof. Nucleic acid molecules encoding the polyprotein construct, prophylactic or therapeutic compositions comprising the polyprotein construct or the nucleic acid molecule, and methods for eliciting an immune response against papillomavirus in a host animal are also provided.

Papillomavirus polyprotein constructs

Peptides, antibodies and recombinant expression systems or cells that contain and express a DNA insert of HPV encoding a region of a papilloma induced or a papilloma protein, such as E6 or E7, are produced. Compositions containing these peptides, antibodies and/or recombinant cells are utilized as immunogenic compositions and in methods for inhibiting and treating HPV infection and tumor initiation and progression. Specific peptides and recombinant cells, such as vaccinia virus and tumor cells, that express epitopic regions of the HPV16 E6 or E7 nucleoprotein are particularly described.

Variants of human papilloma virus (HPV) E6 and E7 proteins able to elicit a humoral and/or cellular immune response against HPV in a host animal but not being cell-transforming in the host animal are disclosed, and are useful in treatment or prevention of diseases or conditions involving HPV.

Variants of human papilloma virus antigens

A vector system for expressing foreign proteins or polypeptides in bacteria such as,is disclosed. The vector system is especially useful in obtaining expression of non-transforming variants of human papilloma virus antigens.

Method for protein expression

Variants of human papillomavirus antigens

Growing community of inventors

Eltham, Australia

Elizabeth Ann Webb